Objective: The use of allogeneic stem cell transplantation (allo-SCT) is increasing and patients are facing physical and mental problems during and after this process. In this study, it was aimed to evaluate the quality of life (QoL) of the patients after at least two or more years from allo-SCT. Material and Methods: 51 transplant patients (TxPs) and 54 healthy controls included in the study. Participants were asked to fill Short Form-36 survey which evaluates QoL in eight main domains. Comparison between TxPs and healthy controls, correlation analyses between remission duration and well being, ROC analysis to find a cut-off value for returning to healthy days were performed. Results: TxPs reported worse QoL than healthy controls. In terms of sex only mental health domain was significantly different where female pariticipants showed better results (p=0.01). Acute or chronic graft versus host disease were not found to have an effect on QoL (p>0.05). Relapsed disease formation had a reducing effect in QoL. Transplant related complications, cytomegalovirus reactivation, conditioning regimen type did not show statistically significant effect on QoL. As the results of the ROC analyses, post-transplant 46th month is found to be a turning point for recovery to healthy status with 68.6% sensitivity and 62.5% spesificity when patients start to realize they regain their health. Conclusion: Allo-SCT has negative effects on patients' physical and social life. In this study it was found that patients start to report similar results to healthy controls in health change approximately after two years from transplantation and the negative effects of transplant were almost completely ceased by 3.5 years.
Keywords: Allogeneic stem cell transplantation; quality of life; surveys and questionnaries
Amaç: Allojenik kök hücre nakli [allogeneic stem cell transplantation (allo-SCT)] kullanımı giderek artmaktadır. Hastalar bu süreç boyunca ve sonrasında, fiziksel ve ruhsal sorunlarla karşı karşıya kalmaktadır. Bu çalışmada, allo-SCT'den en az 2 yıl sonra hastaların yaşam kalitesinin [quality of life (QoL)] değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya 51 nakil hastası [transplant patients (TxPs)] ve 54 sağlıklı kontrol dâhil edildi. Katılımcılardan QoL'yi 8 ana alanda değerlendiren Kısa Form-36 anketini doldurmaları istendi. TxPs ve sağlıklı kontroller arasında karşılaştırma, remisyon süresi ile iyilik hâli arasında korelasyon analizleri, sağlıklı günlere dönüş için bir eşik değeri bulmak için ROC analizi yapıldı. Bulgular: Çoğunlukla TxPs, sağlıklı kontrollerden daha kötü QoL bildirdi. Cinsiyet açısından tek fark ruh sağlığı karşılaştırmasında bulundu ve kadın katılımcıların daha iyi sonuçlar verdiği gözlemlendi (p=0,01). Akut veya kronik graft versus host hastalığının QoL üzerinde bir etkisi bulunmamıştır (p>0,05). Nükseden hastalık oluşumu QoL'de azaltıcı bir etkiye sahip olarak bulundu. Nakil ile ilgili komplikasyonlar, sitomegalovirüs reaktivasyonu, hazırlık rejimi tipi, QoL üzerinde istatistiksel olarak anlamlı bir etki göstermedi. ROC analizlerinin sonuçlarına göre %68,6 sensitivite ve %62,5 spesifite ile transplant sonrası 46. ay, hastaların sağlıklarına kavuştuklarını fark etmeye başlamaları açısından eşik değeri olarak bulunmuştur. Sonuç: allo-SCT'nin hastaların fiziksel ve sosyal yaşamları üzerinde olumsuz etkileri vardır. Bu çalışmada, hastaların nakilden yaklaşık 2 yıl sonra sağlık değişikliğinde sağlıklı kontrollere benzer sonuçlar vermeye başladıkları ve 3,5 yıl sonra naklin olumsuz etkilerinin neredeyse tamamen ortadan kalktığı bulunmuştur.
Anahtar Kelimeler: Allojenik kök hücre nakli; yaşam kalitesi; sörveyler ve anketler
- Arnaout K, Patel N, Jain M, El-Amm J, Amro F, Tabbara IA. Complications of allogeneic hematopoietic stem cell transplantation. Cancer Invest. 2014;32(7):349-62. [Crossref] [PubMed]
- Norkin M, Hsu JW, Wingard JR. Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation. Semin Hematol. 2012;49(1):104-9. [Crossref] [PubMed]
- Ahluwalia R, Yeung P, Tzachanis D. Depression and infection rates in hematopoietic stem cell transplant patients. Biology of Blood and Marrow Transplantation. 2019;25(3):S375-6. [Crossref]
- Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-83. [Crossref] [PubMed]
- Demiral Y, Ergor G, Unal B, Semin S, Akvardar Y, Kivircik B, et al. Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health. 2006;6:247. [Crossref] [PubMed] [PMC]
- Ftronline [İnternet]. [Erişim tarihi: 9 Aralık 2022]. SF-36 (Kısa Form SF-36). Erişim linki: [Link]
- Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey. Manual and Interpretation Guide. 1993;2.
- Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51(11):903-12. [Crossref] [PubMed]
- Ware JE Jr, Gandek B. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):945-52. [Crossref] [PubMed]
- La Nasa G, Caocci G, Efficace F, Dessì C, Vacca A, Piras E, et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood. 2013;122(13):2262-70. [Crossref] [PubMed]
- Morishita S, Kaida K, Ikegame K, Yoshihara S, Taniguchi K, Okada M, et al. Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation. Support Care Cancer. 2012;20(4):821-9. [Crossref] [PubMed]
- Inoue J, Kai M, Doi H, Okamura A, Yakushijin K, Makiura D, et al. Association between physical function and health-related quality of life in survivors of hematological malignancies undergoing hematopoietic stem cell transplantation. Trends in Transplant. 2021;14:1-5. [Crossref]
- Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006;38(4):305-10. [Crossref] [PubMed]
- Worel N, Biener D, Kalhs P, Mitterbauer M, Keil F, Schulenburg A, et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant. 2002;30(9):619-26. [Crossref] [PubMed]
- Sommer M, Nielsen LK, Nielsen LB, Brøndum RF, Nielsen MM, Rytter AS, et al. Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study. Health Qual Life Outcomes. 2021 4;19(1):251. [Crossref] [PubMed] [PMC]
- Dampier C, LeBeau P, Rhee S, Lieff S, Kesler K, Ballas S, et al; Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC) Site Investigators. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011;86(2):203-5. [Crossref] [PubMed] [PMC]
- Yong M, Raj S, Yeoh ZH, Slavin MA, Panek-Hudson Y, Ritchie DS. The long term impact of cytomegalovirus (CMV) viremia on quality of life in allogeneic haematopoietic cell transplant recipients (HCT). Biology of Blood and Marrow Transplantation. 2020;26(3):S359-60. [Crossref]
- Le RQ, Bevans M, Savani BN, Mitchell SA, Stringaris K, Koklanaris E, et al. Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010;16(8):1162-70. [Crossref] [PubMed] [PMC]
.: Process List